In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Big Tech's Growing Biopharma Prominence

Executive Summary

If activity at the recent J.P. Morgan Healthcare Conference is an indication of what is up ahead, 2024 is set to be the year of big tech in biopharma. 

You may also be interested in...



Lilly And Novartis Are First Pharma Partners For Alphabet’s Isomorphic In Drug Discovery

The company’s AlphaFold platform impressed two years ago, and is now extending its machine learning tech into small-molecule drug discovery with big pharma partners.

Bayer’s BD And Licensing Strategy Key To Moving Through Difficult Period

As Bayer moves through a challenging period, business development, licensing and impact investment may help buttress the company’s resilience

What Big Pharmas Are Looking For In Partners

With all signs pointing towards a year ripe with partnering opportunities, four big pharma dealmakers reveal what they are looking for.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148678

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel